GlassScriptPhysician profile
Brian L Henry
NPI 1811124480
$223,791.11
in general payments reported to CMS, 2019-2025
38 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $19K · 2021: $42K · 2022: $43K · 2023: $28K · 2024: $34K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Travel and Lodging: $5,442 · Food and Beverage: $4,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,087.50 |
| Travel and Lodging | $5,441.71 |
| Food and Beverage | $4,630.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $90,436.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $59,262.94 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $18,740.60 | 2019-2025 | Watchman Access System, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15,862.97 | 2020-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $9,227.94 | 2019-2022 | |
| Pfizer International LLC | $7,520.00 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7,315.43 | 2019-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $4,426.83 | 2022-2025 | Amvuttra, Onpattro |
| Lilly USA, LLC | $4,087.50 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,068.19 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $849.32 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $843.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $402.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $282.10 | 2021-2025 | Andexxa, Wainua, Farxiga |
| Novo Nordisk INC | $164.39 | 2024 | Ozempic, Rybelsus, Wegovy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcym INC | $152.46 | 2025 | Perceval |
| Philips North America LLC | $134.99 | 2023-2025 | Extended Holter, (Ck4) Mcot |
| Kowa Pharmaceuticals America, INC. | $127.22 | 2019 | |
| Heartflow, INC. | $106.48 | 2019-2025 | |
| Baxter Healthcare | $101.64 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $94.69 | 2019 | |
| Bridgebio Pharma, INC. | $76.64 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $75.28 | 2022-2024 | Nexletol |
| Janssen Scientific Affairs, LLC | $53.29 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $45.47 | 2019 | |
| Kestra Medical Technology Services, INC. | $40.72 | 2023 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $38.62 | 2023 | Optimizer |
| Irhythm Technologies, INC. | $35.13 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Glaxosmithkline, LLC. | $34.43 | 2024 | Shingrix, Arexvy |
| Vital Connect, INC | $33.48 | 2025 | Vitalpatch Rtm |
| Daiichi Sankyo INC. | $29.97 | 2023-2024 | Injectafer |
| Cardiovascular Systems INC. | $25.99 | 2021 | |
| Sanofi Pasteur INC. | $24.92 | 2020-2021 | |
| Medtronic, INC. | $22.47 | 2021 | |
| Amarin Pharma, INC. | $18.49 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.71 | 2025 | |
| W. L. Gore & Associates, INC. | $12.53 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.